SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

February 03, 2011 09:00 ET

BIOLASE Receives CE Mark Approval for Waterlase® iPlus™ All-Tissue Laser

Commercial Sales Initiated in Europe

IRVINE, CA--(Marketwire - February 3, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it has received Conformite Europeene (CE) Mark approval for the Waterlase® iPlus™ System dual-wavelength all-tissue laser. The Waterlase iPlus, BIOLASE's new flagship laser product, is the most advanced laser in the market and the first major breakthrough in all-tissue laser technology since the Waterlase MD™ was introduced in 2005. Receipt of CE Mark enables BIOLASE to initiate commercial sales of the system throughout the European Union.

"While BIOLASE is currently accepting orders on both the newly launched Waterlase iPlus and our revolutionary iLase™ battery-operated, wireless handheld laser, the products will be formally introduced in Europe at the world's largest dental meeting, the International Dental Show (IDS), in Cologne, Germany, being held March 22-26, 2011," said Chairman and CEO Federico Pignatelli. The Waterlase iPlus and iLase will be in Hall 4.2, stand L060/M061 in the American Pavilion.

BIOLASE is headquartered in Irvine, California, and also maintains a European sales and support subsidiary in Germany, BIOLASE EUROPE GMBH, to cover the European and Middle Eastern markets, and is in the process of setting up an Asian sales and support operation based in Shanghai, China, to cover the rapidly growing Asia-Pacific region. The Company also plans to open a subsidiary in South America in the first quarter of 2011. In North America, the Company is distributing on a direct mode and also through Henry Schein, Inc. (NASDAQ: HSIC) and Benco Dental. Schein International is a distributor in select European countries, Australia and New Zealand.

Pignatelli added, "We are moving very rapidly to commercialize our new flagship laser in all major markets and are encouraged with the speed to which we received this approval. We currently have 26 distributors in Europe, Eastern Europe and the Middle East plus Schein International in Germany, Austria, France, Spain, Portugal, Italy, Belgium, Luxembourg, the Netherlands and the UK."

The Waterlase iPlus, with its Intuitive Power Control, not only addresses the key functional needs for the next generation of laser dentists, but it also delivers double the power and cutting speed with unparalleled control and versatility for all laser dentist users, experienced or novice. Performing most types of procedures with the new Waterlase iPlus provides minimal to no pain or discomfort, minimizes the need for local anesthetic in most restorative cases, eliminates the risk of cross-contamination associated with conventional drills and burs, and results in preserving the tissue biologically intact, and without causing the damaging micro-fractures of the tooth structure and avoiding the necrosis caused by heat and abrasion.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti
    Allen & Caron